Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , Inc., a ... digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims to ... medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, Growers, ...
(Date:6/29/2015)... SAS today announced that data related to its lead ... 1A (CMT1A), is being presented in four posters and one ... Meeting at the Quebec Congress Center in Quebec ... At Poster Viewing Session 4, four posters will ... Poster 23: "A Meta-Analysis Of Randomized Double-Blind ...
(Date:6/29/2015)... ... June 29, 2015 , ... The global microfluidics ... the forecast period (2015 to 2020). The market is mainly driven by the ... funding for R&D. However, lack of adequate healthcare and research infrastructure in emerging ...
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... Sept. 9 EnVivo Pharmaceuticals today announced the appointment of ... officer. DiPalma is responsible for overall financial operations for ... "EnVivo has grown to the point where we ... broad pipeline and increasing business opportunities," said Kees Been, CEO ...
... , DURHAM, N.C., Sept. 9 Oxygen Biotherapeutics, ... is being mailed today, asks shareholders to approve a 1-for-15 reverse ... , "At last years, general annual meeting we ... bulletin board and we promised to seek a listing change as ...
... , , , SAN DIEGO, Sept. 9 ... on the treatment of obesity, today announced that the Company will be speaking ... , , , Morgan Stanley Global Healthcare ... Time: 9:45am Eastern Time, Location: Grand Hyatt Hotel, ...
Cached Biology Technology:EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer 2Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split 2
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ... Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten ... Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die forensische ... Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... NEW YORK (July 1, 2008) -- Clinician-scientists from NewYork-Presbyterian ... important change to guidelines used in the care of ... that following TBI, patients should be given nutritional supplementation ... which they say can improve their chances of survival ...
... (July 1, 2008, New York, NY) The Parkinson,s Disease ... toward its 2008-2009 International Research Grants and Fellowship Program ... 19 Parkinson,s scientists, chosen on April 11 from a ... committee led by Stanley Fahn, M.D., PDF,s Scientific Director. ...
... and going green be easier if you could ... a team of Canadian industry consultants set out ... forthcoming issue of the International Journal of ... The researchers recruited twenty willing households into ...
Cached Biology News:Following traumatic brain injury, balanced nutrition saves lives 2The Parkinson's Disease Foundation awards $950,000 in seed grants 2The Parkinson's Disease Foundation awards $950,000 in seed grants 3Shrinking carbon footprints 2Shrinking carbon footprints 3
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Proline-serine-threonine phosphatase-interacting protein 2...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Biology Products: